The continuous cetuximab group had more elderly patients (age >75 years), more with a WHO performance score of 2, more with BRAF mutations, and more with primary colon cancers (vs rectal) than did the intermittent cetuximab group (Table 1, Table 2). The gene discussed is BRAF; the disease is malignant colon neoplasm.